Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease.

Literature DB >> 19181642

Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease.

Charles A Dinarello.

Abstract

Entities: Disease Gene

Mesh：

Substances：

Year: 2009 PMID： 19181642 PMCID： PMC2664579 DOI： 10.4065/84.2.105

Source DB: PubMed Journal: Mayo Clin Proc ISSN： 0025-6196 Impact factor: 7.616

× No keyword cloud information.

12 in total

1. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.

Authors: Z J Gu; J De Vos; C Rebouissou; M Jourdan; X G Zhang; J F Rossi; J Wijdenes; B Klein
Journal: Leukemia Date: 2000-01 Impact factor: 11.528

2. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma.

Authors: K A Donovan; M Q Lacy; M P Kline; G J Ahmann; J K Heimbach; R A Kyle; J A Lust
Journal: Leukemia Date: 1998-04 Impact factor: 11.528

Review 3. The role of interleukin-1 beta in the pathogenesis of multiple myeloma.

Authors: J A Lust; K A Donovan
Journal: Hematol Oncol Clin North Am Date: 1999-12 Impact factor: 3.722

4. IL-1 is required for tumor invasiveness and angiogenesis.

Authors: Elena Voronov; Dror S Shouval; Yakov Krelin; Emanuela Cagnano; Daniel Benharroch; Yoichiro Iwakura; Charles A Dinarello; Ron N Apte
Journal: Proc Natl Acad Sci U S A Date: 2003-02-21 Impact factor: 11.205

5. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

Authors: Hal M Hoffman; Martin L Throne; N J Amar; Mohamed Sebai; Alan J Kivitz; Arthur Kavanaugh; Steven P Weinstein; Pavel Belomestnov; George D Yancopoulos; Neil Stahl; Scott J Mellis
Journal: Arthritis Rheum Date: 2008-08

6. Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study.

Authors: Hélène Payette; Ronenn Roubenoff; Paul F Jacques; Charles A Dinarello; Peter W F Wilson; Leslie W Abad; Tamara Harris
Journal: J Am Geriatr Soc Date: 2003-09 Impact factor: 5.562

7. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.

Authors: C J Fisher; G J Slotman; S M Opal; J P Pribble; R C Bone; G Emmanuel; D Ng; D C Bloedow; M A Catalano
Journal: Crit Care Med Date: 1994-01 Impact factor: 7.598

8. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.

Authors: R Bataille; B Barlogie; Z Y Lu; J F Rossi; T Lavabre-Bertrand; T Beck; J Wijdenes; J Brochier; B Klein
Journal: Blood Date: 1995-07-15 Impact factor: 22.113

9. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

Authors: Robert A Kyle; Ellen D Remstein; Terry M Therneau; Angela Dispenzieri; Paul J Kurtin; Janice M Hodnefield; Dirk R Larson; Matthew F Plevak; Diane F Jelinek; Rafael Fonseca; Lee Joseph Melton; S Vincent Rajkumar
Journal: N Engl J Med Date: 2007-06-21 Impact factor: 91.245

10. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

Authors: Raphaela Goldbach-Mansky; Natalie J Dailey; Scott W Canna; Ana Gelabert; Janet Jones; Benjamin I Rubin; H Jeffrey Kim; Carmen Brewer; Christopher Zalewski; Edythe Wiggs; Suvimol Hill; Maria L Turner; Barbara I Karp; Ivona Aksentijevich; Frank Pucino; Scott R Penzak; Margje H Haverkamp; Leonard Stein; Barbara S Adams; Terry L Moore; Robert C Fuhlbrigge; Bracha Shaham; James N Jarvis; Kathleen O'Neil; Richard K Vehe; Laurie O Beitz; Gregory Gardner; William P Hannan; Robert W Warren; William Horn; Joe L Cole; Scott M Paul; Philip N Hawkins; Tuyet Hang Pham; Christopher Snyder; Robert A Wesley; Steven C Hoffmann; Steven M Holland; John A Butman; Daniel L Kastner
Journal: N Engl J Med Date: 2006-08-10 Impact factor: 91.245

18 in total

Review 1. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

Authors: S Vincent Rajkumar; Robert A Kyle; Francis K Buadi
Journal: Mayo Clin Proc Date: 2010-10 Impact factor: 7.616

Targeting the pathogenic role of interleukin 1{beta} in the progression of smoldering/indolent myeloma to active disease.

1. Agonist anti-gp130 transducer monoclonal antibodies are human myeloma cell survival and growth factors.

2. Contrast in cytokine expression between patients with monoclonal gammopathy of undetermined significance or multiple myeloma.

Review 3. The role of interleukin-1 beta in the pathogenesis of multiple myeloma.

4. IL-1 is required for tumor invasiveness and angiogenesis.

5. Efficacy and safety of rilonacept (interleukin-1 Trap) in patients with cryopyrin-associated periodic syndromes: results from two sequential placebo-controlled studies.

6. Insulin-like growth factor-1 and interleukin 6 predict sarcopenia in very old community-living men and women: the Framingham Heart Study.

7. Initial evaluation of human recombinant interleukin-1 receptor antagonist in the treatment of sepsis syndrome: a randomized, open-label, placebo-controlled multicenter trial.

8. Biologic effects of anti-interleukin-6 murine monoclonal antibody in advanced multiple myeloma.

9. Clinical course and prognosis of smoldering (asymptomatic) multiple myeloma.

10. Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition.

Review 1. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence.

2. Schnitzler's syndrome associated with pancreatitis: a disease of IL-1 dysregulation.

3. Histone deacetylase inhibitors for treating a spectrum of diseases not related to cancer.

Review 4. Smoldering (asymptomatic) multiple myeloma: revisiting the clinical dilemma and looking into the future.

5. [IL-1 antagonists].

6. The ecology of cancer from an evolutionary game theory perspective.

7. Role of IL-1 beta in the development of human T(H)17 cells: lesson from NLPR3 mutated patients.

8. Cancer phenotype as the outcome of an evolutionary game between normal and malignant cells.

9. Study of C-reactive protein, procalcitonin, and immunocyte ratios in 194 patients with sepsis.

10. Monoclonal Gammopathy of Undetermined Significance (MGUS) in a Man with Fragile X-associated Tremor/Ataxia Syndrome.